XERS

Over the past six months, Xeris Biopharma reported its First Quarter 2026 and Second Quarter 2026 financial results; the Q2 2026 results showed total revenue increasing to over $92 million and net product revenue increasing 34% year-over-year, with Recorlev net revenue up 81%, despite a GAAP EPS loss due to a one-time non-cash convertible note charge. The company tightened its full-year 2026 total revenue guidance to $385 million to $390 million. Xeris hosted a webinar detailing its comprehensive development program for XP-8121, including plans for a Phase 3 registrational study by year-end 2026, with topline results expected in late 2028 and potential FDA approval and launch by 2030, anticipating a peak net revenue potential of $1 billion to $3 billion. Management presented at the Jefferies Global Healthcare Conference and the H.C. Wainwright Global Investment Conference. On June 30, 2026, Xeris announced updates to its Board of Directors, including the naming of CEO John Shannon as Chair of the Board. The stock experienced a significant daily move of -21.9% on November 6, 2025, and over the past 52 weeks, it traded between a high of $10.08 and a low of $5.25, with the share price at $8.20 on September 18, 2026, representing a 4.33% increase over the past year.